Skip to main content

Table 3 Outcome measures at different time periods

From: Impact of Erythropoietin in the management of Hypoxic Ischaemic Encephalopathy in resource-constrained settings: protocol for a randomized control trial

Domain Outcome measure Stage of HIE T1 Discharge T2 4 months T2 6 months T3 12 months T4 18 months T5 24 months
Survival Survival or death X X X X X X X
Neurologic exam at discharge Neurologically normal or abnormal X X      
Cranial Ultrasonography Cranial USS abnormality X X      
Neurologic examination at clinic visits Malawi Developmental Assessment Tool (MDAT) scores    X X X X X
Laboratory levels of EPO, NRBC, and NRBC/100 WBC Levels of NRBC and NRBC/100WBC in relation to outcome X X      
Adverse reactions to EPO Safety of the medications based on the presence or absence of any adverse event   X X X X X X
Gross Motor Function Classification System (GMFCS) assessment system Those with cerebral palsy are further categorized based on features present on standardized neurologic examination using GMFCS    X X X X X
  1. T1− T5 - The five time periods for assessment; NRBC Nucleated red blood cells, GMFCS Gross motor function classification system.